The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study.
Dingwei Ye
No relevant relationships to disclose
Jun Guo
No relevant relationships to disclose
Jae-Lyun Lee
Honoraria - Bayer; Novartis; Pfizer; Sanofi
Ai-Ping Zhou
No relevant relationships to disclose
Yiran Huang
No relevant relationships to disclose
Zhiquan Hu
No relevant relationships to disclose
Cheng Fu
No relevant relationships to disclose
Jiyan Liu
No relevant relationships to disclose
Lin Qi
No relevant relationships to disclose
Hanzhong Li
No relevant relationships to disclose
Qing Zou
No relevant relationships to disclose
Sung Joon Hong
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma
Kathrin Stauch
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Annette Böckenhoff
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Gyunji Kim
Employment or Leadership Position - Bayer; Bayer
XiaoJing Zhang
Employment or Leadership Position - Bayer
Hanjong Ahn
No relevant relationships to disclose
Jianhui Ma
No relevant relationships to disclose